Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 30,526 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 30,526 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the sale, the insider now directly owns 54,322 shares in the company, valued at approximately $1,033,747.66. This represents a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Trading Down 6.5 %

Shares of CNTA opened at $17.79 on Tuesday. The stock’s 50-day moving average price is $16.78 and its 200 day moving average price is $15.49. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of -11.63 and a beta of 1.53. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on CNTA shares. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $25.83.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the period. Walleye Capital LLC acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at approximately $187,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after purchasing an additional 6,785 shares during the period. Finally, Harbour Capital Advisors LLC acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $259,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.